Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Why the study?
Does adding apixaban to antiplatelet therapy reduce recurrent ischemic events in high-risk patients after an acute coronary syndrome?
Population
High-risk patients after an acute coronary syndrome
Comparison
Apixaban 5 mg twice daily added to antiplatelet… vs Antiplatelet therapy alone
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Avoid adding apixaban to antiplatelet therapy after ACS due to excess bleeding; confirms no net ischemic benefit from anticoagulation in this setting.
Key Points
- To evaluate the effects of adding apixaban to antiplatelet therapy in high-risk patients following acute coronary syndrome.
- Randomized trial
- 5 mg apixaban administered twice daily with antiplatelet therapy
- ClinicalTrials.gov number NCT00831441
- Major bleeding events increased with apixaban therapy
- No significant reduction in recurrent ischemic events observed
Structured PICO
Does adding apixaban to antiplatelet therapy reduce recurrent ischemic events in high-risk patients after an acute coronary syndrome?
P
Population
High-risk patients after an acute coronary syndrome
I
Intervention
Apixaban 5 mg twice daily added to antiplatelet therapy
C
Comparator
Antiplatelet therapy alone
O
Outcome
Recurrent ischemic eventshard clinical
Adding apixaban 5 mg twice daily to standard antiplatelet therapy after an acute coronary syndrome causes harm by increasing major bleeding without providing significant ischemic benefit.
Cite This Study
Alexander et al. (2011) studied this question.